CareTrust REIT, Inc
CTRE
$38.95
-1.91%
CareTrust REIT, Inc. is a self-administered real estate investment trust that owns, acquires, finances, develops, and leases skilled nursing, seniors housing, and other healthcare-related properties. The company operates as a pure-play healthcare REIT, generating revenue through triple-net lease agreements where tenants are responsible for all property-level costs, providing a relatively stable income stream. The current investor narrative centers on the REIT's growth through strategic acquisitions in the fragmented healthcare real estate market and its resilience amid demographic tailwinds from an aging population, with recent attention focused on its ability to maintain high occupancy and rent coverage from its operator tenants in a potentially challenging labor and reimbursement environment for the healthcare sector.…
CTRE
CareTrust REIT, Inc
$38.95
Investment Opinion: Should I buy CTRE Today?
Rating & Thesis: Hold. CTRE is a high-quality, growth-oriented healthcare REIT executing superbly, but its premium valuation and proximity to technical resistance limit near-term upside, making it prudent to wait for a better entry point. The bullish institutional ratings (Overweight, Outperform) acknowledge the strong execution but do not offset the valuation concerns given the limited formal analyst coverage.
Supporting Evidence: The stock trades at a forward P/E of 23.21x, a premium to many REITs, justified by its 117% revenue growth and 67% net margin. However, the P/S ratio of 15.45x and EV/EBITDA of 17.44x are elevated. The 3.52% dividend yield is attractive and well-covered by an 80.91% payout ratio. Strong free cash flow of $379M TTM and a pristine balance sheet (D/E 0.22) are clear positives, but the stock's 37% annual run-up suggests much good news is priced in.
Risks & Conditions: The two biggest risks are valuation compression and growth deceleration. This Hold rating would upgrade to a Buy if the stock experiences a pullback towards the $35-$37 support zone (a ~10% decline) or if forward P/E compresses below 20x while growth remains intact. It would downgrade to Sell if quarterly revenue growth decelerates sharply below 25% YoY or if net margins contract significantly. Relative to its own history and growth profile, the stock is fairly valued to slightly overvalued, demanding flawless execution to maintain its current price level.
Sign up to view all
CTRE 12-Month Price Forecast
The analysis yields a neutral stance based on a clash between stellar fundamentals and full valuation. CTRE's operational performance is exemplary, with explosive growth, high margins, and a clean balance sheet. However, the stock's 37% annual gain has brought its valuation multiples to levels that demand perfect continued execution. With limited analyst coverage adding uncertainty, the risk/reward appears balanced in the near term. The stance would upgrade to bullish on a ~10% pullback that improves the entry valuation, or on clear evidence that the current growth rate is sustainable. It would turn bearish if the next quarterly report shows a sharp growth deceleration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareTrust REIT, Inc's 12-month outlook, with a consensus price target around $50.64 and implied upside of +30.0% versus the current price.
Average Target
$50.64
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$31 - $51
Analyst target range
Insufficient analyst coverage available. The provided data indicates only one analyst is formally tracked, which is minimal for a company of this market cap. This limited coverage typically signifies it is a smaller or more niche name within the REIT universe, leading to potentially higher volatility and less efficient price discovery as institutional interest may be lower. The lack of a consensus target price and detailed rating distribution makes it difficult to gauge professional sentiment, though recent institutional ratings from firms like Wells Fargo ('Overweight'), RBC Capital ('Outperform'), and UBS ('Buy') suggest a bullish bias among those who do cover it. The wide estimated EPS range for the single analyst, from $1.42 to $1.90, underscores the high uncertainty inherent with limited coverage, and investors must rely more heavily on their own fundamental and technical analysis when evaluating the stock.
Bulls vs Bears: CTRE Investment Factors
The bull case, supported by explosive revenue growth, exceptional margins, and a fortress balance sheet, currently holds stronger evidence. The stock's 37% annual gain and proximity to 52-week highs reflect this optimism. However, the bear case presents a credible counterpoint centered on peakish valuation and the sustainability of acquisition-fueled growth. The single most important tension in the investment debate is whether CTRE can continue its acquisition spree at a pace that justifies its premium valuation, or if growth will decelerate, triggering a painful valuation compression from its current high multiples.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 117.13% year-over-year to $135.05 million, demonstrating an aggressive and successful acquisition strategy. Sequential quarterly growth from $71.65M to $135.05M in 2025 confirms the momentum is accelerating, not a one-time event.
- Exceptional Profitability & Margins: The company boasts a trailing net margin of 67.26% and a Q4 2025 net margin of 82.41%, indicating highly efficient operations under its triple-net lease model. Strong free cash flow of $379.04M TTM provides ample internal capital for dividends and further growth.
- Robust Balance Sheet & Low Volatility: A low debt-to-equity ratio of 0.22 and a current ratio of 1.54 provide financial flexibility and resilience. A beta of 0.79 indicates the stock is 21% less volatile than the market, offering defensive characteristics in a portfolio.
- Strong Technical Momentum: The stock has gained 37.39% over the past year, outperforming the S&P 500, and is trading at 95% of its 52-week high of $41.72, signaling sustained bullish momentum. The 3-month gain of 4.61% suggests the uptrend remains intact despite recent consolidation.
Bearish
- Valuation at Peak Historical Levels: The trailing P/E of 22.97x is near the higher end of its historical range, leaving little room for multiple expansion and increasing sensitivity to earnings disappointment. Elevated P/S (15.45x) and EV/EBITDA (17.44x) ratios suggest much future growth is already priced in.
- Limited Analyst Coverage & High Uncertainty: With only one formal analyst tracked, price discovery is less efficient and institutional interest may be lower, potentially leading to higher volatility. The wide analyst EPS range ($1.42 to $1.90) underscores significant uncertainty in forward estimates.
- Near-Term Technical Resistance: Trading at $39.50, just below the 52-week high of $41.72, creates a major resistance level that could trigger profit-taking and a pullback. The recent 1-month price decline of -1.03% and a sharp drop on March 20th to $36.10 show vulnerability to volatility.
- Dependence on Acquisition-Led Growth: The 117% revenue surge is driven by acquisitions, a strategy that is capital-intensive and may not be sustainable indefinitely. Future growth and margin stability depend on the company's ability to continue sourcing and integrating accretive deals.
CTRE Technical Analysis
The stock is in a sustained uptrend, having gained 37.39% over the past year, significantly outperforming the broader market's 34.9% gain. Currently trading at $39.50, the price sits at approximately 95% of its 52-week high of $41.72, indicating the stock is near its peak and may be testing a major resistance level; this positioning suggests strong momentum but also raises the risk of a pullback if the resistance holds. The 1-month price change of -1.03% shows a slight pullback, contrasting with the strong 3-month gain of 4.61%, signaling a potential consolidation or short-term profit-taking phase after the robust longer-term advance. This divergence from the 1-year trend could represent a healthy pause before another leg higher, especially given the stock's beta of 0.79 indicates it is 21% less volatile than the market, which may cushion sharper declines. Key technical support is anchored near the 52-week low of $27.27, while immediate resistance is the 52-week high of $41.72; a decisive breakout above $41.72 would signal a continuation of the bullish trend, whereas a failure could lead to a retreat toward the $36-$38 consolidation zone observed in the price data from late 2025 to early 2026. The stock's beta of 0.79 suggests it offers lower systematic risk than the market, which is a consideration for defensive positioning within a portfolio.
Beta
0.79
0.79x market volatility
Max Drawdown
-12.3%
Largest decline past year
52-Week Range
$27-$42
Price range past year
Annual Return
+35.3%
Cumulative gain past year
| Period | CTRE Return | S&P 500 |
|---|---|---|
| 1m | +6.3% | +12.6% |
| 3m | +5.0% | +2.5% |
| 6m | +12.4% | +4.3% |
| 1y | +35.3% | +28.4% |
| ytd | +7.3% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTRE Fundamental Analysis
Revenue growth has been robust and accelerating, with Q4 2025 revenue of $135.05 million representing a 117.13% year-over-year increase; this surge is part of a clear multi-quarter acceleration, as sequential quarterly revenues grew from $71.65 million in Q1 2025 to $135.05 million in Q4 2025. The company's single reportable segment of healthcare real estate investments is driving this growth, likely fueled by an aggressive acquisition strategy. Profitability is strong and margins are expanding, with Q4 2025 net income of $111.29 million and a net margin of 82.41%, up significantly from a net margin of 83.82% in Q4 2024. The gross margin for Q4 2025 was 58.93%, and the operating margin was 64.10%, demonstrating highly efficient operations for a REIT model where most costs are passed to tenants. The balance sheet is healthy with a conservative debt profile, evidenced by a low debt-to-equity ratio of 0.22 and a strong current ratio of 1.54. The company generates substantial cash flow, with trailing twelve-month free cash flow of $379.04 million, providing ample internal funding for growth and dividends, as reflected in an 80.91% payout ratio and a dividend yield of 3.52%.
Quarterly Revenue
$135052000.0B
2025-12
Revenue YoY Growth
+1.17%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$379037000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTRE Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 22.97x, and the forward PE is 23.21x, indicating the market expects earnings to remain roughly stable in the near term, with no significant growth or contraction priced in. Compared to the broader Real Estate sector, a trailing PE in the low-20s is generally in line or at a slight premium for a healthcare REIT with CareTrust's growth profile and high margins. The stock trades at a Price-to-Sales ratio of 15.45x and an EV/EBITDA of 17.44x, which are elevated but justified by its superior net margin of 67.26% and strong cash flow generation. Historically, the stock's current trailing PE of 22.97x is above its own historical range observed in the provided data, which has fluctuated between approximately 18x and 85x over recent years; trading near the higher end of its historical band suggests the market is pricing in optimistic expectations for continued execution, leaving less room for multiple expansion and increasing sensitivity to any earnings disappointment.
PE
23.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -1017x~617x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage (D/E of 0.22 is low) but rather the sustainability of its growth model. The 117% YoY revenue surge is acquisition-driven, and a slowdown in deal flow could cause growth to decelerate sharply, jeopardizing the premium valuation. While margins are currently stellar (net margin 67.26%), they are susceptible to compression if acquired properties have lower rent coverage or higher capital needs. The company's revenue is concentrated in a single segment—healthcare real estate—making it a pure-play bet on that sector's health.
Market & Competitive Risks: The stock trades at a trailing P/E of 22.97x, which is above its own historical average and represents a premium for the REIT sector. This creates valuation compression risk if interest rates rise or growth expectations moderate. Its beta of 0.79 indicates lower market correlation, but the stock remains sensitive to sector-specific headwinds like regulatory changes in healthcare reimbursement. Competitive pressure in acquiring quality healthcare properties could drive up prices and reduce future returns on invested capital.
Worst-Case Scenario: A perfect storm would involve a halt to the acquisition pipeline coinciding with a downturn in the healthcare property sector, leading to tenant distress and rent coverage issues. This could trigger multiple compression towards its historical lower P/E range and a retreat to its 52-week low. From the current price of $39.50, a decline to the 52-week low of $27.27 represents a catastrophic loss of approximately -31%. A more realistic severe bear case might see a drop to the $30-$32 range, representing a -19% to -24% downside, driven by an earnings miss and sector de-rating.
FAQ
The key risks are: 1) Valuation Risk: Trading at a P/E of 22.97x near its 52-week high, the stock could decline sharply if growth slows. 2) Growth Sustainability Risk: The 117% revenue surge is acquisition-dependent; a slowdown in deal flow would hurt the growth narrative. 3) Sector Risk: As a healthcare REIT, it is exposed to tenant risks like rising labor costs and changes in government reimbursement policies. 4) Liquidity & Coverage Risk: With only one formal analyst, the stock has less institutional scrutiny and potentially higher volatility. The valuation and growth sustainability risks are currently the most severe.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $38 and $42, assuming growth moderates but remains strong and the valuation holds. The Bull Case (25% probability) projects a breakout above resistance to $44-$48, driven by continued blockbuster acquisition news. The Bear Case (15% probability) warns of a drop to $30-$35 if growth stalls and multiples contract. The Base Case is most likely, anchored by the assumption that CTRE's growth will decelerate from its extreme pace but remain robust enough to support a premium, albeit not expanding, valuation.
CTRE appears fairly valued to slightly overvalued relative to its own history. Its trailing P/E of 22.97x is above its historical average, indicating the market is paying a premium for its recent explosive growth. Compared to the broader Real Estate sector, the multiple is at a premium but may be justified by its superior net margin of 67.26% and growth profile. The valuation implies the market expects CTRE to continue its acquisition-driven growth at a high rate. If that growth slows, the stock is vulnerable to multiple compression, suggesting the current price leaves little margin for error.
CTRE is a good stock for investors already positioned for a long-term hold, but it is not an optimal buy at the current moment. The company's fundamentals are excellent, with 117% revenue growth, a 67% net margin, and a strong balance sheet. However, the stock trades at a premium valuation (P/E 22.97x) and is within 5% of its 52-week high, suggesting limited near-term upside and heightened sensitivity to any misstep. For new money, it would be a better buy on a pullback to the $35-$37 range. Income-focused investors may find the 3.52% yield attractive, but must accept the potential for price volatility.
CTRE is more suitable for a long-term investment horizon of 3-5 years. While it offers a 3.52% yield, its primary appeal is capital appreciation through growth, which is a longer-term story. Its beta of 0.79 provides some defensive characteristics, but its premium valuation and acquisition-driven model require time to play out and validate. Short-term traders face the challenge of a stock near technical resistance with rich valuation, increasing the risk of a pullback. A long-term horizon allows investors to ride through volatility and benefit from the demographic tailwinds in healthcare real estate.
